Journal
PROGRESS IN CARDIOVASCULAR DISEASES
Volume 51, Issue 5, Pages 416-433Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pcad.2008.03.002
Keywords
-
Categories
Funding
- Jazz Pharmaceuticals
- Merck Company
- National Space Agency [NNJ05HF 06G]
- National Institutes of Health [HL65270, HL83075]
- The Children's Foundation Endowment for Sleep Research
- The Commonwealth of Kentucky Research Challenge Trust
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL107160, R01HL065270, U01HL083075] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Obstructive Sleep Apnea Syndrome (OSAS) is a common condition in children, and is characterized by intermittent partial or complete occlusion of the upper airway during sleep, leading to profound disturbances in homeostatic gas exchange, frequent arousals and disturbed sleep architecture. Pediatric OSAS is associated with a multitude of end-organ morbidities, most of which have been uncovered in the last decade. Of particular interest are the cardiovascular complications that may develop in children with OSAS, since they are posited to have not only an immediately significant impact on cardiovascular health during childhood, but may also affect cardiovascular outcomes later during adult life. In this review, we will present the specific cardiovascular complications that have thus far been described in children with OSAS, with reference to pertinent mechanisms, and potential implications. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available